Autoimmune hemolytic anemia laboratory findings

Jump to navigation Jump to search

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia laboratory findings

CDC on Autoimmune hemolytic anemia laboratory findings

Autoimmune hemolytic anemia laboratory findings in the news

Blogs on Autoimmune hemolytic anemia laboratory findings

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S; Shyam Patel [2], Irfan Dotani [3]

Overview

Laboratory findings in patients with autoimmune hemolytic anemia include anemia, positive Coombs test, positive indirect antiglobulin test, hemoglobinuria, low haptoglobin, increased spherocytes, and elevated lactate dehydrogenase (LDH). Not all patients will have all of these findings. The severity of hemolysis will determine the degree of laboratory abnormalities.

Laboratory Findings

A variety of laboratory tests can be used to help diagnose autoimmune hemolytic anemia.

  • Complete blood count:
  • Coombs' test:
    • This is also known as the direct antiglobulin test.
    • The Coombs test assesses for the presence of antibodies attached to a patient's red blood cells, which is a key feature of autoimmune hemolytic anemia.
    • The test is performed by collecting peripheral blood containing red blood cells, which presumably harbor antibodies on their surfaces, then adding in a Coombs reagent and assessing for agglutination. If agglutination occurs in the presence of the Coomb's reagent, this indicates the presence of antibodies on the surface of red blood cells.[1]
    • Of note, the Coomb's test can be negative in 3-10% of patients.[2] The reasons for a negative Coombs' test include inability to detect a minimal amount of immunoglobulin G (IgG) on the red blood cell surface.[3] Another reason for a false-negative Coombs' test is the presence of immunoglobulin A (IgA) on the red blood cell surface, instead of IgG.
    • Other laboratory tests that can be done in the setting of false-negative Coombs test include flow cytometry and antibody elution techniques.[2]
  • Indirect antiglobulin test:
    • This is also known as the indirect Coomb's test.
    • The indirect antiglobulin test involves detection of circulating anti-red blood cell antibodies.
    • The test involves using reagent red blood cell, which are commercially available, and adding the patient's serum (which presumably contains the anti-red blood cell antibodies). Then, the Coombs's reagent is added, and agglutination is observed.
  • Hemoglobin in the urine:
    • Elevated urine hemosiderin indicates intravascular hemolysis.
  • Reticulocyte count:
    • Patients with autoimmune hemolytic anemia will mount a compensatory response to red blood cell destruction by increasing erythroid production from the bone marrow.
    • The immediate precursor to mature red blood cells is the reticulocyte.
    • An elevated reticulocyte count is an indication of active hemolysis.
  • Serum bilirubin:
    • Bilirubin is a breakdown product of biliverdin, which is a breakdown product of heme, which is found in hemoglobin.
    • Upon red blood cell destruction in autoimmune hemolytic anemia, free heme is released into the circulation and is eventually broken down to bilirubin.
    • An elevated total bilirubin and indirect (unconjugated) bilirubin is an indication of hemolysis.
    • Patients with autoimmune hemolytic anemia typically have total bilirubin level greater than 1 g/dl and indirect bilirubin of 50% or greater of the total bilirubin level.
  • Serum haptoglobin:
    • Bilirubin binds to haptoglobin, and therefore haptoglobin decreases in autoimmune hemolytic anemia.
    • The level is typically less than 8 mg/dl in patients with active hemolytic anemia.
  • Serum LDH:
  • Peripheral blood smear:
    • The peripheral blood smear allows for direct visualization of the morphology of red blood cells.
    • In autoimmune hemolytic anemia, red blood cells have a spherical shape and are known as spherocytes.
    • This is in contrast to the normal shape of red blood cells, which is biconcave with a large surface area.
    • The pathophysiology behind the formation of spherocytes is that splenic macrophages remove a portion of the red blood cell membrane, resulting in loss of the normal biconcave shape of erythrocytes.

References

  1. Biswas S. Chandrashekhar P. Varghese M (2007). "Coomb's Positive Hemolytic Anemia Due To Insect Bite". Oman Med J. 22 (3): 62–3. PMC 3294156. PMID 22400097.
  2. 2.0 2.1 Berentsen S, Sundic T (2015). "Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy". Biomed Res Int. 2015: 363278. doi:10.1155/2015/363278. PMC 4326213. PMID 25705656.
  3. Park SY, Kim S, Kim ES, Choi SU, Hyun HJ, Ahn JY; et al. (2012). "A Case of Non-Hodgkin's Lymphoma in Patient with Coombs' Negative Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura". Cancer Res Treat. 44 (1): 69–72. doi:10.4143/crt.2012.44.1.69. PMC 3322204. PMID 22500164.

Template:WikiDoc Sources